VENCLEXTA when used with rituximab

In a clinical trial with 389 people with CLL who had tried at least one previous treatment, VENCLEXTA + rituximab was studied against a commonly used chemoimmunotherapy regimen, bendamustine + rituximab (BR).

Achieving remission was one goal of treatment

Of the 194 patients who were treated with VENCLEXTA + rituximab, over 9 out of 10 (92%) people achieved some level of remission or response to therapy. These responses included mostly partial remissions (PR=82%, nPR=2%) and some complete remissions (CR+CRi=8%).

Definitions for some of the response types in the VENCLEXTA + rituximab study: 

  • Partial remission (PR) means the cancer is greatly improved and there are fewer cancer cells, but evidence of the cancer is still in your body
  • Nodular partial remission (nPR) means that most signs and symptoms of cancer disappeared for a period of time except for some remaining cancer cells in your bone marrow
  • Complete remission (CR) means that all signs and symptoms of cancer disappeared for a period of time, although cancer may still be in your body
  • Complete remission with incomplete marrow recovery (CRi) means that most signs and symptoms of cancer disappeared for a period of time except that platelet, white blood cell, or red blood cell counts remained low

VENCLEXTA when used alone

VENCLEXTA taken alone was studied in 3 clinical trials. In a clinical trial of 106 people with CLL with 17p deletion who had tried at least 1 other treatment: 

  • 8 in 10 people (80%) in the trial achieved some level of remission (CR+CRi=8%, nPR=3%, PR=70%)

In a clinical trial of 59 people with CLL with or without 17p deletion who had tried at least 1 other treatment:

  • ~7 in 10 people (71%) in the trial achieved some level of remission (CR+CRi=7%, PR=64%)

In a clinical trial of 127 people with CLL with or without 17p deletion who had tried ibrutinib or idelalisib:

  • 7 in 10 people (70%) in the trial achieved some level of remission (CR+CRi=1%, PR=69%)